As­traZeneca nabs break­through sta­tus, as $7B ADC races to block­buster sta­tus

A rapid breast can­cer ap­proval came just be­fore New Year’s for As­traZeneca and Dai­ichi Sankyo’s bil­lion-dol­lar an­ti­body drug con­ju­gate En­her­tu, but the plan was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.